Hyperion Therapeutics Announces Second Quarter 2013 Financial Results Teleconference and Webcast
August 08, 2013 16:30 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will host a teleconference and webcast with management to provide a...
Hyperion Therapeutics Announces Larry J. Singer as Vice President, Manufacturing
August 06, 2013 09:15 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that Larry J. Singer has joined the company as vice president, Manufacturing. Mr....
Hyperion Therapeutics Announces Three New Additions to Its Senior Leadership Team
July 17, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 17, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company has added three new executives to its leadership team: senior vice...
Hyperion Therapeutics to Present at the Eighth Annual JMP 2013 Global Healthcare Securities Conference
July 02, 2013 09:00 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the eighth annual JMP 2013 Global...
Hyperion Therapeutics Announces RAVICTI and BUPHENYL Pharmacokinetic Analyses Reported in The Journal of Clinical Pharmacology
June 18, 2013 08:00 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 18, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that population pharmacokinetic (PK) modeling and dosing simulations were...
Hyperion Therapeutics Acquires Worldwide Rights to BUPHENYL
June 03, 2013 09:00 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the completion of its acquisition of BUPHENYL® (sodium phenylbutyrate)...
Hyperion Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
May 29, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 29, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Jefferies 2013 Global Healthcare...
Hyperion Therapeutics Added to NASDAQ Biotechnology Index (NBI)
May 16, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 16, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index®...
Hyperion Therapeutics Announces First Quarter 2013 Operating Results
May 09, 2013 16:05 ET
|
Hyperion Therapeutics, Inc.
First Net Sales of RAVICTI Post-approval Reported at $0.8 Million
Strong Cash Position of $102.7 million
SOUTH SAN FRANCISCO, Calif., May 9, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc....
Hyperion Therapeutics to Report First Quarter 2013 Financial Results After Market on May 9, 2013
May 06, 2013 18:36 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 6, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report financial results for the first quarter 2013 ended March 31,...